Symbols / NAGE $4.83 +0.52%
NAGE Chart
About
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 386.39M |
| Enterprise Value | 323.37M | Income | 17.38M | Sales | 129.42M |
| Book/sh | 0.96 | Cash/sh | 0.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | 117 | IPO | — |
| P/E | 24.12 | Forward P/E | 13.99 | PEG | — |
| P/S | 2.99 | P/B | 5.04 | P/C | — |
| EV/EBITDA | 21.44 | EV/Sales | 2.50 | Quick Ratio | 3.73 |
| Current Ratio | 4.86 | Debt/Eq | 3.68 | LT Debt/Eq | — |
| EPS (ttm) | 0.20 | EPS next Y | 0.34 | EPS Growth | -41.60% |
| Revenue Growth | 16.20% | Earnings | 2026-05-06 | ROA | 10.23% |
| ROE | 28.35% | ROIC | — | Gross Margin | 64.28% |
| Oper. Margin | 6.21% | Profit Margin | 13.43% | Shs Outstand | 80.08M |
| Shs Float | 52.89M | Short Float | 12.26% | Short Ratio | 7.00 |
| Short Interest | — | 52W High | 14.69 | 52W Low | 4.39 |
| Beta | 2.23 | Avg Volume | 1.20M | Volume | 661.47K |
| Target Price | $13.60 | Recom | Strong_buy | Prev Close | $4.80 |
| Price | $4.83 | Change | 0.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.60
Mean price target
2. Current target
$4.78
Latest analyst target
3. DCF / Fair value
$1.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.78
Low
$12.00
High
$18.00
Mean
$13.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Canaccord Genuity | Buy → Buy | $13 |
| 2025-11-05 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2025-08-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-06-10 | main | Canaccord Genuity | Buy → Buy | $16 |
| 2025-06-06 | main | Roth Capital | Buy → Buy | $23 |
| 2025-05-27 | init | Canaccord Genuity | — → Buy | $13 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-10 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-05 | main | Ladenburg Thalmann | Buy → Buy | $8 |
| 2024-11-06 | main | Roth MKM | Buy → Buy | $8 |
| 2024-11-04 | main | HC Wainwright & Co. | Buy → Buy | $8 |
- Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance Mon, 12 Jan 2026 08
- Niagen Bioscience sheds side business to focus on longevity science - Stock Titan hu, 26 Feb 2026 08
- The Bull Case For Niagen Bioscience (NAGE) Could Change Following Record 2025 Results And Injectable Expansion - simplywall.st Sun, 08 Mar 2026 08
- HC Wainwright Issues Optimistic Outlook for NAGE Earnings - MarketBeat Fri, 06 Mar 2026 08
- Niagen Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:NAGE) 2026-03-04 - Seeking Alpha Wed, 04 Mar 2026 22
- Liquidity Mapping Around (NAGE) Price Events - Stock Traders Daily Wed, 04 Mar 2026 09
- Niagen Bioscience more than doubles 2025 profit as Tru Niagen sales jump - Stock Titan Wed, 04 Mar 2026 21
- Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance Wed, 04 Mar 2026 08
- We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve - simplywall.st ue, 11 Nov 2025 08
- Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market (NASDAQ:NAGE) - Seeking Alpha Mon, 05 Jan 2026 08
- Niagen Bioscience (NASDAQ:NAGE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat Sat, 07 Mar 2026 08
- New $59 Niagen NanoCloud sachets show smoother, more hydrated skin in 2 weeks - Stock Titan ue, 10 Mar 2026 12
- Investors in Niagen Bioscience (NASDAQ:NAGE) have seen incredible returns of 320% over the past three years - Yahoo Finance Wed, 17 Dec 2025 08
- Niagen Bioscience (NAGE) Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook - simplywall.st hu, 05 Mar 2026 14
- Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance hu, 24 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6685 | 45616 | — | Purchase at price 6.81 - 6.85 per share. | PAMIR OZAN | Chief Financial Officer | — | 2025-11-14 00:00:00 | D/I |
| 1 | 66667 | 220001 | — | Conversion of Exercise of derivative security at price 3.30 per share. | FRIED ROBERT N. | Chief Executive Officer | — | 2025-04-09 00:00:00 | D |
| 2 | 273 | 2146 | — | Purchase at price 7.86 per share. | LOPEZ CARLOS LUIS | General Counsel | — | 2025-03-07 00:00:00 | D |
| 3 | 50001 | 183004 | — | Conversion of Exercise of derivative security at price 3.66 per share. | JAKSCH FRANK LOUIS JR | Director | — | 2024-12-13 00:00:00 | D |
| 4 | 37161 | 229956 | — | Sale at price 6.19 per share. | JAKSCH FRANK LOUIS JR | Director | — | 2024-12-13 00:00:00 | D |
| 5 | 2907 | 21397 | — | Purchase at price 7.36 per share. | PAMIR OZAN | Chief Financial Officer | — | 2024-11-22 00:00:00 | D |
| 6 | 23000 | 38320 | — | Conversion of Exercise of derivative security at price 1.64 - 1.67 per share. | PATRICK KRISTIN | Director | — | 2024-08-23 00:00:00 | D |
| 7 | 23000 | 82110 | — | Sale at price 3.57 per share. | PATRICK KRISTIN | Director | — | 2024-08-23 00:00:00 | D |
| 8 | 11408715 | 38105108 | — | Purchase at price 3.34 per share. | CHAU HOI SHUEN SOLINA HOLLY | Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-20 00:00:00 | I |
| 9 | 11408715 | 38105108 | — | Sale at price 3.34 per share. | LI KA SHING | Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-20 00:00:00 | I |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 88.29K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.04 | 0.03 | 0.00 | 0.00 |
| NormalizedEBITDA | 13.76M | 9.21M | -3.89M | -16.74M |
| TotalUnusualItems | 1.98M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 1.98M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | 17.38M | 8.55M | -4.94M | -16.54M |
| ReconciledDepreciation | 1.45M | 1.48M | 1.71M | 1.88M |
| ReconciledCostOfRevenue | 46.23M | 38.01M | 32.79M | 29.25M |
| EBITDA | 15.75M | 9.21M | -3.89M | -16.74M |
| EBIT | 14.30M | 7.73M | -5.60M | -18.63M |
| NetInterestIncome | 2.13M | 1.13M | 661.00K | 3.00K |
| InterestIncome | 2.13M | 1.13M | 661.00K | 3.00K |
| NormalizedIncome | 15.49M | 8.55M | -4.94M | -16.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 17.38M | 8.55M | -4.94M | -16.54M |
| TotalExpenses | 115.13M | 91.87M | 89.17M | 90.68M |
| TotalOperatingIncomeAsReported | 16.28M | 7.73M | -5.60M | -18.63M |
| DilutedAverageShares | 85.44M | 78.12M | 74.98M | 69.73M |
| BasicAverageShares | 79.18M | 75.93M | 74.98M | 69.73M |
| DilutedEPS | 0.20 | 0.11 | -0.07 | -0.24 |
| BasicEPS | 0.22 | 0.11 | -0.07 | -0.24 |
| DilutedNIAvailtoComStockholders | 17.38M | 8.55M | -4.94M | -16.54M |
| NetIncomeCommonStockholders | 17.38M | 8.55M | -4.94M | -16.54M |
| NetIncome | 17.38M | 8.55M | -4.94M | -16.54M |
| NetIncomeIncludingNoncontrollingInterests | 17.38M | 8.55M | -4.94M | -16.54M |
| NetIncomeContinuousOperations | 17.38M | 8.55M | -4.94M | -16.54M |
| TaxProvision | 810.00K | 305.00K | 0.00 | |
| PretaxIncome | 18.19M | 8.86M | -4.94M | -16.54M |
| OtherIncomeExpense | 1.77M | 2.08M | ||
| OtherNonOperatingIncomeExpenses | -214.00K | 2.08M | ||
| SpecialIncomeCharges | 1.98M | 0.00 | ||
| OtherSpecialCharges | -1.98M | |||
| NetNonOperatingInterestIncomeExpense | 2.13M | 1.13M | 661.00K | 3.00K |
| TotalOtherFinanceCost | -3.00K | 55.00K | ||
| InterestIncomeNonOperating | 2.13M | 1.13M | 661.00K | 3.00K |
| OperatingIncome | 14.30M | 7.73M | -5.60M | -18.63M |
| OperatingExpense | 68.89M | 53.86M | 56.38M | 61.42M |
| ResearchAndDevelopment | 6.33M | 6.02M | 4.96M | 4.83M |
| SellingGeneralAndAdministration | 62.56M | 47.84M | 51.42M | 56.60M |
| SellingAndMarketingExpense | 35.51M | 29.47M | 26.44M | 28.31M |
| GeneralAndAdministrativeExpense | 27.06M | 18.38M | 24.98M | 28.29M |
| OtherGandA | 27.06M | 18.38M | 24.98M | 28.29M |
| GrossProfit | 83.19M | 61.59M | 50.78M | 42.80M |
| CostOfRevenue | 46.23M | 38.01M | 32.79M | 29.25M |
| TotalRevenue | 129.42M | 99.60M | 83.57M | 72.05M |
| OperatingRevenue | 129.42M | 99.60M | 83.57M | 72.05M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 79.71M | 77.33M | 74.98M | 74.57M |
| ShareIssued | 79.71M | 77.33M | 74.98M | 74.57M |
| TotalDebt | 2.82M | 2.65M | 3.28M | 4.26M |
| TangibleBookValue | 70.87M | 45.73M | 27.95M | 28.00M |
| InvestedCapital | 76.53M | 46.09M | 28.46M | 28.67M |
| WorkingCapital | 76.89M | 46.15M | 28.91M | 28.70M |
| NetTangibleAssets | 70.87M | 45.73M | 27.95M | 28.00M |
| CapitalLeaseObligations | 2.82M | 2.65M | 3.28M | 4.26M |
| CommonStockEquity | 76.53M | 46.09M | 28.46M | 28.67M |
| TotalCapitalization | 76.53M | 46.09M | 28.46M | 28.67M |
| TotalEquityGrossMinorityInterest | 76.53M | 46.09M | 28.46M | 28.67M |
| StockholdersEquity | 76.53M | 46.09M | 28.46M | 28.67M |
| GainsLossesNotAffectingRetainedEarnings | -9.00K | -4.00K | -4.00K | -3.00K |
| ForeignCurrencyTranslationAdjustments | -9.00K | -4.00K | -4.00K | -3.00K |
| RetainedEarnings | -164.53M | -181.91M | -190.46M | -185.49M |
| AdditionalPaidInCapital | 240.99M | 227.93M | 218.84M | 214.09M |
| CapitalStock | 79.00K | 77.00K | 75.00K | 74.00K |
| CommonStock | 79.00K | 77.00K | 75.00K | 74.00K |
| TotalLiabilitiesNetMinorityInterest | 29.87M | 22.18M | 26.51M | 25.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.95M | 4.24M | 5.89M | 7.52M |
| NonCurrentDeferredLiabilities | 8.14M | 2.58M | 3.31M | 3.96M |
| NonCurrentDeferredRevenue | 2.67M | 2.58M | 3.31M | 3.96M |
| LongTermDebtAndCapitalLeaseObligation | 1.81M | 1.66M | 2.58M | 3.56M |
| LongTermCapitalLeaseObligation | 1.81M | 1.66M | 2.58M | 3.56M |
| CurrentLiabilities | 19.92M | 17.95M | 20.62M | 17.87M |
| CurrentDeferredLiabilities | 399.00K | 611.00K | 195.00K | 157.00K |
| CurrentDeferredRevenue | 399.00K | 611.00K | 195.00K | 157.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.00M | 994.00K | 702.00K | 696.00K |
| CurrentCapitalLeaseObligation | 1.00M | 994.00K | 702.00K | 696.00K |
| PayablesAndAccruedExpenses | 18.52M | 16.34M | 19.73M | 17.02M |
| CurrentAccruedExpenses | 7.72M | 7.82M | 9.49M | 7.34M |
| Payables | 10.80M | 8.53M | 10.23M | 9.68M |
| AccountsPayable | 10.80M | 8.53M | 10.23M | 9.68M |
| TotalAssets | 106.41M | 68.28M | 54.96M | 54.06M |
| TotalNonCurrentAssets | 9.60M | 4.18M | 5.43M | 7.49M |
| OtherNonCurrentAssets | 425.00K | 368.00K | 383.00K | 497.00K |
| GoodwillAndOtherIntangibleAssets | 5.66M | 359.00K | 510.00K | 671.00K |
| OtherIntangibleAssets | 5.66M | 359.00K | 510.00K | 671.00K |
| NetPPE | 3.52M | 3.45M | 4.54M | 6.32M |
| AccumulatedDepreciation | -5.75M | -5.76M | -5.41M | -4.55M |
| GrossPPE | 9.27M | 9.21M | 9.95M | 10.88M |
| Leases | 2.21M | 2.21M | 2.15M | 2.06M |
| ConstructionInProgress | 45.00K | 86.00K | 5.00K | 172.00K |
| OtherProperties | 5.94M | 6.02M | 6.81M | 7.87M |
| MachineryFurnitureEquipment | 1.08M | 894.00K | 987.00K | 778.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 96.81M | 64.10M | 49.53M | 46.57M |
| OtherCurrentAssets | 1.31M | 2.48M | 2.45M | 2.97M |
| AssetsHeldForSaleCurrent | 541.00K | 0.00 | ||
| RestrictedCash | 152.00K | 152.00K | 152.00K | 152.00K |
| PrepaidAssets | 1.86M | |||
| Inventory | 20.42M | 9.19M | 14.53M | 14.68M |
| OtherInventories | 494.00K | 548.00K | 500.00K | 516.00K |
| FinishedGoods | 9.86M | 5.81M | 5.96M | 7.90M |
| WorkInProcess | 3.09M | 2.13M | 3.54M | 2.99M |
| RawMaterials | 7.47M | 757.00K | 4.48M | 3.28M |
| Receivables | 9.74M | 7.77M | 5.23M | 8.48M |
| AccountsReceivable | 9.74M | 7.77M | 5.23M | 8.48M |
| AllowanceForDoubtfulAccountsReceivable | -147.00K | -95.00K | -68.00K | -122.00K |
| GrossAccountsReceivable | 9.89M | 7.86M | 5.30M | 8.60M |
| CashCashEquivalentsAndShortTermInvestments | 64.64M | 44.51M | 27.17M | 20.29M |
| CashAndCashEquivalents | 64.64M | 44.51M | 27.17M | 20.29M |
| CashFinancial | 28.02M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 13.21M | 11.95M | 6.97M | -15.43M |
| RepurchaseOfCapitalStock | -251.00K | 0.00 | ||
| RepaymentOfDebt | -12.00K | -11.00K | -15.00K | -16.00K |
| IssuanceOfCapitalStock | 0.00 | 7.75M | 26.74M | |
| CapitalExpenditure | -292.00K | -163.00K | -148.00K | -334.00K |
| InterestPaidSupplementalData | 1.00K | 1.00K | 2.00K | 1.00K |
| EndCashPosition | 64.79M | 44.66M | 27.32M | 20.44M |
| BeginningCashPosition | 44.66M | 27.32M | 20.44M | 28.22M |
| ChangesInCash | 20.13M | 17.34M | 6.88M | -7.78M |
| FinancingCashFlow | 6.92M | 5.37M | -90.00K | 7.65M |
| CashFlowFromContinuingFinancingActivities | 6.92M | 5.37M | -90.00K | 7.65M |
| NetOtherFinancingCharges | -67.00K | -52.00K | -75.00K | -77.00K |
| ProceedsFromStockOptionExercised | 7.25M | 5.43M | 0.00 | 0.00 |
| NetCommonStockIssuance | -251.00K | 0.00 | 0.00 | 7.75M |
| CommonStockPayments | -251.00K | 0.00 | ||
| CommonStockIssuance | 0.00 | 7.75M | 26.74M | |
| NetIssuancePaymentsOfDebt | -12.00K | -11.00K | -15.00K | -16.00K |
| NetLongTermDebtIssuance | -12.00K | -11.00K | -15.00K | -16.00K |
| LongTermDebtPayments | -12.00K | -11.00K | -15.00K | -16.00K |
| InvestingCashFlow | -292.00K | -143.00K | -143.00K | -334.00K |
| CashFlowFromContinuingInvestingActivities | -292.00K | -143.00K | -143.00K | -334.00K |
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | -292.00K | -143.00K | -143.00K | -334.00K |
| SaleOfPPE | 0.00 | 20.00K | 5.00K | 0.00 |
| PurchaseOfPPE | -292.00K | -163.00K | -148.00K | -334.00K |
| OperatingCashFlow | 13.50M | 12.11M | 7.12M | -15.10M |
| CashFlowFromContinuingOperatingActivities | 13.50M | 12.11M | 7.12M | -15.10M |
| ChangeInWorkingCapital | -8.23M | 3.22M | 4.62M | -6.01M |
| ChangeInOtherWorkingCapital | -122.00K | -316.00K | -606.00K | -396.00K |
| ChangeInOtherCurrentLiabilities | -949.00K | -615.00K | -519.00K | -463.00K |
| ChangeInPayablesAndAccruedExpense | 4.11M | 139.00K | 2.71M | 112.00K |
| ChangeInAccruedExpense | 1.84M | 1.21M | 2.16M | 856.00K |
| ChangeInPayable | 2.27M | -1.07M | 553.00K | -744.00K |
| ChangeInAccountPayable | 2.27M | -1.07M | 553.00K | -744.00K |
| ChangeInPrepaidAssets | 1.12M | -45.00K | 631.00K | -872.00K |
| ChangeInInventory | -11.63M | 5.33M | 152.00K | -1.08M |
| ChangeInReceivables | -756.00K | -1.28M | 2.25M | -3.32M |
| ChangesInAccountReceivables | -756.00K | -1.28M | 2.25M | -3.32M |
| OtherNonCashItems | -1.95M | -3.52M | 15.00K | -237.00K |
| StockBasedCompensation | 6.07M | 3.66M | 4.75M | 5.74M |
| ProvisionandWriteOffofAssets | -1.22M | -1.25M | 964.00K | 63.00K |
| AssetImpairmentCharge | 0.00 | 3.00K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 1.45M | 1.48M | 1.71M | 1.88M |
| DepreciationAndAmortization | 1.45M | 1.48M | 1.71M | 1.88M |
| AmortizationCashFlow | 173.00K | 151.00K | 158.00K | 186.00K |
| AmortizationOfIntangibles | 173.00K | 151.00K | 158.00K | 186.00K |
| Depreciation | 1.28M | 1.33M | 1.55M | 1.70M |
| OperatingGainsLosses | 4.00K | -19.00K | -5.00K | 7.00K |
| GainLossOnSaleOfPPE | 4.00K | -19.00K | -5.00K | 7.00K |
| NetIncomeFromContinuingOperations | 17.38M | 8.55M | -4.94M | -16.54M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NAGE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|